上海复星医药（集团）股份有限公司（复星医药，股票代码：02196）于2026年9月10日向香港联交所提交翌日披露报表，披露当日于港交所场内回购股份事宜。
根据公告，复星医药于2026年9月10日回购1,290,000股H股，占该公司现有已发行股本约0.24%。每股回购价格介于港币16.40元至16.87元，合计耗资约21,414,640港元，折合约2141.46万港元。回购完成后，公司已发行股本变更为538,907,500股，库藏股增至13,033,000股。
公告同时显示，公司于2026年6月16日获得回购授权，可购回股数为54,097,150股；截至此次回购前，已购回2,064,000股，占授权可回购股数约0.38%。
公司确认上述回购行为符合香港联合交易所有限公司证券上市规则及相关法律法规。该公告由公司董事陈玉卿签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.